IMVTImmunovant, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- —
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY |
|---|---|---|---|---|---|---|
| Net income | −$157M | −$211M | −$259M | −$414M | −$506M | 22% |
| Operating cash flow | −$106M | −$188M | −$214M | −$376M | −$407M | 8.4% |
| Capex | $254K | $197K | $360K | $759K | $8K | 99% |
| Stock-based comp | $34M | $32M | $41M | $49M | $56M | 13% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $723K · 8
- Net
- −$723K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | — | — | 155 | 129 |
| FY2025 | — | — | 107 | 93 |
| FY2024 | — | — | 201 | 96 |
| FY2023 | — | — | 97 | 89 |
| FY2022 | — | — | 34 | 89 |